11 Worst Performing Stocks in S&P 500 So Far in 2025

8. West Pharmaceutical Services, Inc. (NYSE:WST)

YTD Decline in Share Price: -34.67%

West Pharmaceutical Services, Inc. (NYSE:WST) is a global manufacturer of high-quality injectable solutions and services. The company is a trusted partner to drug developers worldwide in ensuring effective containment and delivery of critical medicines for patients. Through its vast network spread across 50 sites, including 25 manufacturing facilities, WST delivers over 41 billion components and devices every year.

It is among the worst performing stocks in 2025, with a year-to-date slump of nearly 35%. Shares fell sharply after West Pharmaceutical Services, Inc. (NYSE:WST)’s Q4 2024 earnings call on February 13, in which the company announced significant decreases in gross profit margin and adjusted operating profit margin, which impacted its earnings.

Investor sentiment also took a hit from West Pharmaceutical Services, Inc. (NYSE:WST)’s weak financial outlook for fiscal 2025. The company stated that it anticipates net sales to be in the range of $2.875 billion to $2.905 billion, and adjusted diluted EPS between $6.00 and $6.20. This was lower than Wall Street analysts’ forecasts of $3.04 billion and $7.44, respectively.

However, the stock has shown some signs of recovery over the past week, gaining nearly 6%, after West Pharmaceutical Services, Inc. (NYSE:WST) reported financial results for the first quarter of fiscal 2025 on April 24. The company posted net sales of $698 million, representing an organic year-over-year growth of 2.1%. Adjusted diluted EPS was logged at $1.45, beating expectations by 23 cents.

West Pharmaceutical Services, Inc. (NYSE:WST) has also raised its initial guidance for 2025. It now expects net sales of $2.945 billion to $2.975 billion, and EPS in the range of $6.15 to $6.35.